title: Current Standards and Novel Treatment Options for Metastatic Pancreatic Adenocarcinoma.
abstract: Pancreatic cancer is one of the most lethal solid tumors. The prognosis of metastatic pancreatic adenocarcinoma remains dismal, with a median survival of less than 1 year, due in large part to the fact that pancreatic adenocarcinoma is notoriously refractory to chemotherapy. However, there recently have been significant improvements in outcomes for patients with pancreatic adenocarcinoma: ongoing trials have shown promise, and these may lead to still further progress. Here we review the current treatment paradigms for metastatic disease, focusing on ways to ameliorate symptoms and lengthen survival. We then summarize recent advances in our understanding of the molecular and cellular aspects of pancreatic cancer. Finally, we outline new approaches currently under development for the treatment of metastatic disease, arising from our improved understanding of the genetic and nongenetic alterations within pancreatic cancer cells-and of interactions between cancer cells, the tumor microenvironment, and the immune system.
authors.forename: Benjamin A
authors.initials: BA
authors.lastname: Weinberg
authors.forename: Cinthya S
authors.initials: CS
authors.lastname: Yabar
authors.forename: Jonathan R
authors.initials: JR
authors.lastname: Brody
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Pishvaian
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000235:genetics; D060908:CTLA-4 Antigen / Q000037:antagonists & inhibitors; D002986:Clinical Trials as Topic; D006801:Humans; D009362:Neoplasm Metastasis; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors
chemical_list: D060908:CTLA-4 Antigen; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor